Vertex Pharmaceuticals, Inc.’s recent filing unveils that its SVP & Chief Accounting Officer Ambrose Kristen unloaded Company’s shares for reported $0.1 million on Apr 02 ’24. In the deal valued at $419.00 per share,240 shares were sold. As a result of this transaction, Ambrose Kristen now holds 7,500 shares worth roughly $3.05 million.
Then, Arbuckle Stuart A sold 5,034 shares, generating $2,142,974 in total proceeds. Upon selling the shares at $425.70, the EVP, COO now owns 49,691 shares.
Before that, ALTSHULER DAVID sold 4,239 shares. Vertex Pharmaceuticals, Inc. shares valued at $1,804,542 were divested by the EVP, Global Research and CSO at a price of $425.70 per share. As a result of the transaction, ALTSHULER DAVID now holds 25,813 shares, worth roughly $10.5 million.
Wolfe Research initiated its Vertex Pharmaceuticals, Inc. [VRTX] rating to an Outperform in a research note published on February 15, 2024; the price target was $515. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who decreased its forecast for the stock in early February from “an Outperform” to “an In-line”. Bernstein also remained covering VRTX and has decreased its forecast on February 02, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating. Robert W. Baird revised its rating on January 31, 2024. It rated VRTX as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of VRTX
On Friday, Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] saw its stock jump 0.66% to $406.67. Over the last five days, the stock has lost -2.71%. Vertex Pharmaceuticals, Inc. shares have fallen nearly -0.05% since the year began. Nevertheless, the stocks have risen 29.34% over the past one year. While a 52-week high of $448.40 was reached on 01/30/24, a 52-week low of $314.33 was recorded on 04/05/24. SMA at 50 days reached $420.17, while 200 days put it at $379.63. A total of 0.7 million shares were traded, compared to the trading of 0.73 million shares in the previous session.
Levels Of Support And Resistance For VRTX Stock
The 24-hour chart illustrates a support level at 401.69, which if violated will result in even more drops to 396.71. On the upside, there is a resistance level at 410.79. A further resistance level may holdings at 414.91. The Relative Strength Index (RSI) on the 14-day chart is 40.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -7.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.68%. Stochastics %K at 15.72% indicates the stock is a buying.
How much short interest is there in Vertex Pharmaceuticals, Inc.?
A steep rise in short interest was recorded in Vertex Pharmaceuticals, Inc. stocks on Mar 15, 2024, growing by 0.0 shares to a total of 4.13 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 4.13 million shares.
